In a report released on February 20, Joseph Schwartz from Leerink Partners maintained a Buy rating on Travere Therapeutics (TVTX – Research Report), with a price target of $42.00.
Joseph Schwartz’s rating is based on Travere Therapeutics’ strong performance and growth potential. The company reported impressive fourth-quarter sales for its product Filspari, which treats IgA nephropathy, showing a significant increase compared to the previous quarter. This growth is supported by robust patient demand, evidenced by a notable rise in patient start forms.
Furthermore, the company’s strategic approach, including anticipated regulatory advancements in treating focal segmental glomerulosclerosis (FSGS), suggests a promising future. With the potential for a market launch for FSGS treatments in the latter half of 2025, accompanied by a 75% probability of success, Schwartz sees substantial revenue opportunities. Despite the stock’s past strong performance, the analyst believes there is further potential for growth, justifying the Buy rating and maintaining a target price of $42.
In another report released on February 21, Scotiabank also reiterated a Buy rating on the stock with a $32.00 price target.